4335-77-7 Usage
Description
2-Cyclohexylmandelic acid is an organic compound that serves as an intermediate in the synthesis of various pharmaceutical compounds. It is derived from the indole alkaloid found in the leaves of Lespedeza bicolor var. japonica and is characterized by its white solid appearance. When pure, it is a colorless oil, and its MeOH solution exhibits specific absorption maxima in the ultraviolet spectrum. The crystalline hydrochloride form has a melting point of 163-164°C, while the picrate and styphnate forms also exhibit distinct melting points and physical properties.
Uses
Used in Pharmaceutical Industry:
2-Cyclohexylmandelic acid is used as an intermediate in the synthesis of various pharmaceutical compounds, including oxybutynin (O868525), Oxybutynin HCl, and Oxyphenonium Bromide. Its role in the synthesis process is crucial for the development of these medications, which are used to treat different medical conditions.
As an intermediate in the synthesis of oxybutynin (O868525), 2-Cyclohexylmandelic acid plays a vital role in producing a medication that is primarily used to treat overactive bladder, urinary frequency, and urinary incontinence. Oxybutynin works by relaxing the muscles of the bladder, allowing for better control over urination.
In the synthesis of Oxybutynin HCl, 2-Cyclohexylmandelic acid contributes to the creation of a hydrochloride salt form of oxybutynin, which enhances the drug's solubility and bioavailability, making it more effective for treating the same medical conditions as oxybutynin.
Furthermore, 2-Cyclohexylmandelic acid is also used as an intermediate in the synthesis of Oxyphenonium Bromide, a medication that serves as an anticholinergic agent. It is primarily used to treat conditions such as peptic ulcer, gastroesophageal reflux disease, and irritable bowel syndrome by reducing the production of stomach acid and relaxing the muscles in the gastrointestinal tract.
References
Morimoto, Oshio., Annalen, 682, 212 (1965)
Check Digit Verification of cas no
The CAS Registry Mumber 4335-77-7 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 4,3,3 and 5 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 4335-77:
(6*4)+(5*3)+(4*3)+(3*5)+(2*7)+(1*7)=87
87 % 10 = 7
So 4335-77-7 is a valid CAS Registry Number.
InChI:InChI=1/C14H18O3/c15-13(16)14(17,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1,3-4,7-8,12,17H,2,5-6,9-10H2,(H,15,16)/p-1/t14-/m0/s1
4335-77-7Relevant articles and documents
Isothiourea-Catalyzed Acylative Kinetic Resolution of Tertiary α-Hydroxy Esters
Greenhalgh, Mark D.,Laina-Martín, Víctor,Neyyappadath, Rifahath M.,Qu, Shen,Smith, Andrew D.,Smith, Samuel M.
supporting information, p. 16572 - 16578 (2020/09/09)
A highly enantioselective isothiourea-catalyzed acylative kinetic resolution (KR) of acyclic tertiary alcohols has been developed. Selectivity factors of up to 200 were achieved for the KR of tertiary alcohols bearing an adjacent ester substituent, with both reaction conversion and enantioselectivity found to be sensitive to the steric and electronic environment at the stereogenic tertiary carbinol centre. For more sterically congested alcohols, the use of a recently-developed isoselenourea catalyst was optimal, with equivalent enantioselectivity but higher conversion achieved in comparison to the isothiourea HyperBTM. Diastereomeric acylation transition state models are proposed to rationalize the origins of enantiodiscrimination in this process. This KR procedure was also translated to a continuous-flow process using a polymer-supported variant of the catalyst.
Nitrilases
-
Paragraph 0495, (2015/09/22)
The invention relates to nitrilases and to nucleic acids encoding the nitrilases. In addition, methods of designing new nitrilases and methods of use thereof are also provided. The nitrilases have increased activity and stability at increased pH and temperature.
SUBSTITUTED PHENYLCYCLOHEXYLGLYCOLATES
-
Page/Page column 53, (2009/10/06)
Disclosed herein are substituted phenylcyclohexylglycolate-based muscarinic acetylcholine receptor modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
